Benefits
Body fat reduction
A meta-analysis of 18 RCTs confirms CLA supplementation produces a modest but statistically significant reduction in body fat mass (approximately 0.05 kg/week or ~0.7 kg over 12 weeks). The t10,c12 isomer specifically reduces adipocyte size and fat storage by inhibiting lipoprotein lipase and increasing fat oxidation in muscle tissue.
Lean body mass preservation
CLA simultaneously reduces fat mass while preserving or slightly increasing lean body mass — producing favorable changes in body composition without caloric restriction. The c9,t11 isomer supports muscle protein synthesis via PPAR-γ modulation, contributing to the lean mass-preserving effect observed in clinical trials.
Immune effects (laboratory and animal studies only)
Laboratory and animal studies report that the c9,t11 CLA isomer can alter immune cell activity, such as NK cell activity and cytokine production. These are preclinical findings, not immune outcomes measured in people taking CLA supplements, and CLA is not a treatment for cancer or any other disease.
Blood sugar: mixed human evidence, including worsened insulin sensitivity
Human evidence on CLA and blood sugar is mixed and includes clear harm. In a 12-week randomized trial in obese men, the t10,c12 isomer that drives CLA's fat-loss effect raised insulin resistance by 19 percent and fasting glucose by 4 percent versus placebo, and lowered HDL cholesterol. Some trials in other groups report small improvements, but because the isomer sold for body composition has been shown to worsen insulin sensitivity, CLA should not be taken to improve glucose control.
Mechanism of action
Lipoprotein lipase inhibition and adipocyte apoptosis
The t10,c12 CLA isomer inhibits lipoprotein lipase (LPL) in adipose tissue — reducing fatty acid uptake into fat cells — while simultaneously inducing apoptosis (programmed death) of differentiated adipocytes. This dual mechanism reduces both fat storage efficiency and existing adipocyte number, contributing to fat mass reduction over time.
PPAR-α activation and fat oxidation enhancement
CLA isomers activate peroxisome proliferator-activated receptor alpha (PPAR-α) in muscle and liver tissue, upregulating genes for fatty acid oxidation (CPT-1, MCAD, acyl-CoA oxidase). Increased fat oxidation rates shift substrate utilization toward fat, reducing fat accumulation while sparing muscle glycogen.
Stearoyl-CoA desaturase (SCD-1) inhibition
The t10,c12 isomer specifically inhibits stearoyl-CoA desaturase 1 (SCD-1) — a key lipogenic enzyme that converts saturated fatty acids to monounsaturated forms required for fat storage. SCD-1 inhibition reduces the efficiency of fat synthesis and storage in adipose tissue.
Clinical trials
Evidence review and pooled analysis of 18 randomized, placebo-controlled trials examining CLA supplementation (typically 3.2-6.4 g/day, mixed t10,c12 and c9,t11 isomers) on body fat mass and lean body mass. (Am J Clin Nutr)
Pooled across 18 clinical trials.
CLA produced statistically significant but clinically modest reduction in body fat mass (-0.05 kg/week; ~0.7 kg over 12 weeks). Effects plateau after ~6 months. Note: effects are small in absolute terms — CLA is not a meaningful weight loss intervention. Some safety concerns: t10,c12 isomer associated with insulin resistance, hepatic steatosis, and lipid profile changes (increased Lp(a)) in some trials. Overall risk-benefit favors caution.
Randomized, double-blind, placebo-controlled trial of Tonalin® CLA (3.4 g/day, 50:50 t10,c12 / c9,t11 isomers) vs olive oil placebo in 60 overweight adults for 12 weeks. (J Nutr)
60 overweight or obese adults (BMI 25–35). Randomized double-blind, 5 groups: placebo (9 g olive oil) or 1.7, 3.4, 5.1, or 6.8 g CLA per day × 12 weeks. 47 completed.
CLA at 3.4 g/day and 6.8 g/day produced statistically significant reductions in body fat mass (DXA) vs placebo. No clear dose-response above 3.4 g/day. Lean body mass not adversely affected. Foundational dose-response trial supporting 3.4 g/day as effective dose; this was a key early Tonalin®-era CLA study.